Asset
Naltrexone hydrochloride
Ensysce Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05043766 | phase1 | completed | 2021-09-08 | 2022-03-21 | Ensysce Biosciences | Evaluation of Oral PF614 Relative to OxyContin (PF614-102) |
| NCT05090280 | phase1 | completed | 2021-12-01 | 2023-04-26 | Ensysce Biosciences | Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101) |
| NCT02454712 | phase1 | completed | 2016-11-16 | 2018-01-18 | Ensysce Biosciences | Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) |
FDA applications (0)
This company has no applications containing this asset.